Fabbrini, Elisa

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 2,100

Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity

Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 972

Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease

Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology

Liver Disease Diagnosis and TreatmentLipid metabolism and disorders

Cited by 631

Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

Korenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 592

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 498

Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss

Gregor, M. F., Yang, L., Fabbrini, E., Mohammed, B. S., Eagon, J. C., Hotamisligil, G. S., & Klein, S. (2009) · Diabetes

Endoplasmic Reticulum Stress and DiseaseAdipokines, Inflammation, and Metabolic Diseases

Cited by 488

Gastric bypass and banding equally improve insulin sensitivity and β cell function

Bradley, D., Conte, C., Mittendorfer, B., Eagon, J. C., Varela, J. E., Fabbrini, E., Gastaldelli, A., Chambers, K. T., Su, X., Okunade, A., et al. (2012) · Journal of Clinical Investigation

Bariatric Surgery and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 244

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentLipid metabolism and disorders

Cited by 192

Metabolically normal obese people are protected from adverse effects following weight gain

Fabbrini, E., Yoshino, J., Yoshino, M., Magkos, F., Tiemann Luecking, C., Samovski, D., Fraterrigo, G., Okunade, A. L., Patterson, B. W., & Klein, S. (2015) · Journal of Clinical Investigation

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 172

Multiorgan insulin sensitivity in lean and obese subjects

Conte, C., Fabbrini, E., Kars, M., Mittendorfer, B., Patterson, B. W., & Klein, S. (2012) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 99

Fundamentals of Cardipmetabolic Risk Factor Reduction: Achieving and Maintaining Weight Loss with Pharmacotherapy or Bariatric Surgery

Fabbrini, E., & Klein, S. (2008) · Clinical Cornerstone

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 9